Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Response Study to Evaluate the Efficacy and Safety of E6742 in Subjects With Systemic Lupus Erythematosus

NCT07515014 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT07515014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07515014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Response Study to Evaluate the Efficacy and Safety of E6742 in Subjects With Systemic Lupus Erythematosus
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 31, 2026
Completion date
March 1, 2029
Enrollment
256 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus